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The transcriptional profile of coronary
arteritis in Kawasaki disease
Anne H. Rowley1,2,4*, Kristine M. Wylie5,6, Kwang-Youn A. Kim3, Adam J. Pink1, Amy Yang3, Rebecca Reindel1,4,10,
Susan C. Baker7, Stanford T. Shulman1,4, Jan M. Orenstein8, Mark W. Lingen9, George M. Weinstock6,11
and Todd N. Wylie5,6

Abstract
Background: Kawasaki Disease (KD) can cause potentially life-threatening coronary arteritis in young children, and
has a likely infectious etiology. Transcriptome profiling is a powerful approach to investigate gene expression in
diseased tissues. RNA sequencing of KD coronary arteries could elucidate the etiology and the host response, with
the potential to improve KD diagnosis and/or treatment.
Methods: Deep RNA sequencing was performed on KD (n = 8) and childhood control (n = 7) coronary artery tissues,
revealing 1074 differentially expressed mRNAs. Non-human RNA sequences were subjected to a microbial discovery
bioinformatics platform, and microbial sequences were analyzed by Metastats for association with KD.
Results: T lymphocyte activation, antigen presentation, immunoglobulin production, and type I interferon response
were significantly upregulated in KD arteritis, while the tumor necrosis factor α pathway was not differentially
expressed. Transcripts from known infectious agents were not specifically associated with KD coronary arteritis.
Conclusions: The immune transcriptional profile in KD coronary artery tissues has features of an antiviral immune
response such as activated cytotoxic T lymphocyte and type I interferon-induced gene upregulation. These results
provide new insights into the pathogenesis of KD arteritis that can guide selection of new immunomodulatory
therapies for high-risk KD patients, and provide direction for future etiologic studies.
Keywords: Kawasaki disease, Coronary artery aneurysm, Arteritis, Childhood, Innate immune response, Acquired
immune response

Background
Transcriptome profiling of infected tissues, or “dual RNAsequencing” allows for unbiased simultaneous gene expression evaluation of pathogen and host [1]. Kawasaki
Disease (KD) is an acute febrile illness of young childhood
that can cause medium-sized muscular arteritis, most critically affecting the coronary arteries, and a large body of
clinical, epidemiologic, and experimental evidence points
to an infectious cause [2, 3]. Severely affected infants and

young children develop coronary artery aneurysms and
are at risk for myocardial infarction and sudden death
[3]. It has been difficult to improve diagnosis and treatment of KD because of a lack of understanding of the
etiology and pathogenesis. The purpose of this study
was to identify specific cellular pathways and infectious
agents in KD coronary arteritis by transcriptome profiling, to elucidate the pathogenesis of the disease.
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* Correspondence: a-rowley@northwestern.edu
Presented in part at the American Heart Association Annual Meeting
November 15–19, 2014, Chicago, IL and at the Eleventh International
Kawasaki Disease Symposium, February 3–6, 2015, Honolulu, HI.
1
Department of Pediatrics, Northwestern University Feinberg School of
Medicine, 310 E Superior Street, Morton 4-685B, Chicago, IL 60611, USA
2
Department of Microbiology and Immunology, Northwestern University
Feinberg School of Medicine, Chicago, IL, USA
Full list of author information is available at the end of the article

Patients and controls

The study was approved by the Institutional Review
Board of The Ann & Robert H. Lurie Children’s Hospital
of Chicago. The KD cases occurred widely throughout the
United States over the last three decades. Informed consent was obtained at the primary institution in five cases;
in the remaining three KD cases and all the control cases,
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tissues were archival and de-identified. Six KD patients
were male and two were female. Five were Caucasian, one
Hispanic, one African-American, and one of unknown
ethnicity. The mean age of the KD patients was 15 months
with a median age of 7 months. Eight control cases were
male and 3 were female. The mean age of the control
patients was 15 months with a median age of 5 months.
Data deposited at Gene Expression Omnibus, National
Center for Biotechnology Information (GEO) cannot be
potentially used to re-identify individuals from the study.
Clinical information on the KD patients is given in Table 1.
All patients had coronary artery abnormalities and all were
fatal cases except for KD3, who underwent heart transplant; the coronary artery light and electron microscopic
findings for KD patients 1–3 and 5–8 are described in our
pathologic study [4] (Tables 1 and 2). Additional information for KD patient 4 is provided in Additional file 1: Supplemental Methods. Childhood controls had normal
coronary artery histology; their diagnoses are given in
Table 2. Three of the KD patients did not receive any
therapy between fever onset and death/transplant and
one received only aspirin and dipyridamole (KD1-4,
“untreated” group). One patient received IGIV alone,
two received IGIV and corticosteroid, and one patient received IGIV, corticosteroid, and infliximab (KD5-8,
“treated” group).
RNA isolation and quality control analyses

RNA was isolated from formalin-fixed, paraffin-embedded
KD and control tissue sections using the RNeasy kit designed for these tissues (Qiagen, Valencia, CA). RNA samples meeting the quality standards described in Additional
file 1: Supplemental Methods were subjected to ribosomal
RNA subtraction using the Ribo-Zero human rRNA subtraction kit (Epicentre, Madison, WI) prior to sequencing.
High-throughput RNA sequencing

Preparation of cDNA libraries and Illumina HiSeq2000
RNA sequencing were performed at the University of
Utah Microarray Core Facility (Salt Lake City, UT).
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Sequence alignment and normalization

For RNA sequencing analysis, TopHat (Bowtie version
2.1.0) [5] was used to align reads to the human reference GRCh37-lite (accession id: GCA_000001405.1),
and HTseq version 0.6.1 in “union” mode [6] was used
to determine read counts. DESeq was used for variance
stabilizing normalization and determination of differential
expression based on a model using the negative binomial
distribution [7]. Additional information on alignments can
be found in Additional file 1: Table S1.
Pathways analysis

The data were analyzed using iReport™ (Ingenuity Systems, Redwood City, CA, www.ingenuity.com), with fold
change of at least 1.5 and q-value of ≤ 0.05 as significance criteria for differentially expressed genes between
KD patients and controls. The primary analysis was of
CA gene expression in 8 KD patients compared to 7
childhood controls. Subgroup analyses were also performed for the CA transcriptome of 4 untreated KD patients compared to 7 controls, and 4 treated KD patients
compared to 7 controls.
Cluster and principal components analyses

Hierarchical cluster analysis with mean linkage function
(hclust function in base R) was used to cluster the
samples by expression profiles. Principal components
analysis was run to estimate the variances explained by
the first and second principal components (prcomp
function in base R).
Real-time PCR

Differential expression by real-time PCR were performed
on KD and control coronary artery formalin-fixed, paraffinembedded tissue RNAs using the comparative CT method
[8]. The differential expression was compared using variances estimated by empirical Bayes models. We controlled
for false discovery rate to account for multiple testing under
dependency using adjusted p-values [9].

Table 1 Clinical data on Kawasaki disease children whose coronary artery tissues were tested in this study
Case #

Time since onset

KD therapy

Category

Pathology study case # [4]

RNA tested by

KD1
KD2

2.5 weeks

None

Untreated

4

HTS, PCR

4 weeks

ASA, dipyridamole

Untreated

16

HTS

KD3

5 months

None

Untreated

26

HTS, PCR

KD4

7 months

None

Untreated

NA

HTS, PCR

KD5

3.5 weeks

IGIV, ASA, steroid

Treated

11

HTS, PCR

KD6

4 weeks

IGIV, ASA, steroid, infliximab

Treated

13

HTS, PCR

KD7

3 weeks

IGIV, ASA

Treated

7

HTS, PCR

KD8

5 weeks

IGIV, ASA, steroid

Treated

18

HTS

HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR, ASA aspirin
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Table 2 Clinical data on control children whose coronary artery tissues were tested in this study
Control #

Diagnosis

C1

Enterobacter sepsis, pulmonary hemorrhage, neurologic devastation from herpes simplex virus encephalitis

RNA tested by
HTS

C2

Pneumococcal meningitis, disseminated intravascular coagulation

HTS, PCR

C3

Prematurity, neurologic devastation secondary to Serratia meningitis, chronic lung disease

HTS

C4

Meconium aspiration, pulmonary hemorrhage

HTS

C5

Developmental delay, seizures, fever

HTS

C6

Prematurity, cerebral hemorrhage, bronchopulmonary dysplasia, and pneumonia

HTS, PCR

C7

Cholestasis, renal tubular acidosis, agenesis corpus callosum, dehydration

HTS

C8

Congenital diaphragmatic hernia, pulmonary hypoplasia

PCR

C9

Hypotonia, subdural and liver hematomas

PCR

C10

Congenital sacrococcygeal teratoma

PCR

C11

Hypoplastic left heart, respiratory syncytial virus infection

PCR

HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR

Microbial analyses

Viral sequences were identified based on nucleotide and
translated amino acid sequence alignments as described
[10]. Sequences from cellular microbes were identified
using Real Time Genomics Map and Species programs,
version 3.4.3 (Real Time Genomics, Hamilton, New
Zealand, http://realtimegenomics.com) to align sequences
against the Human Microbiome Project’s microbial reference genome database (http://hmpdacc.org/HMREFG/),
and by classifying sequences with MetaPhlAn [11]. Metastats was used to test for sequences that were differentially
abundant in KD cases and controls [12].

Results
Deep RNA sequencing of KD and pediatric control
coronary arteries

To evaluate the transcriptome of KD arteritis, we compared the RNA expression of KD coronary artery tissues
with those of non-inflamed coronary artery tissues from
pediatric patients with non-KD illnesses as controls. The
analysis pathway is shown in Fig. 1. The pathologic features of the coronary arteries in the KD patients are
described in our prior study [4]; all showed subacute/
chronic arteritis and luminal myofibroblastic proliferation (Fig. 2a). All primary data can be accessed at NCBI
GEO GSE64486. Sequencing yielded a total of 40–120
million RNA sequencing reads/sample. About 50–90 %
of the reads for each tissue sample mapped to the human genome. DEseq analysis yielded 1074 genes that
were differentially expressed in 8 KD compared with 7
childhood control coronary arteries (Fig. 2b and c and
Additional file 1: Table S2). Strikingly, heat map analysis
of differentially expressed genes in KD and control coronary artery tissues showed that gene expression in KD
patients did not cluster by age, time since onset of KD,
or treatment, supporting the analysis of the 8 KD tissue

samples together (Fig. 2b and c). The lack of clustering
by time since onset of KD is consistent with our pathologic
study demonstrating persistence of subacute arteritis for
months to years after the onset [4]. It is notable in Fig. 2b
and c that the gene expression profiles of the two patients
with the longest time interval since onset, KD3 and KD4,
fall directly in the center of the KD patient group. The lack
of clustering by treatment is likely explained by persistent
arteritis in the treated patients despite therapy. Principal
components analysis also demonstrated that gene expression profiles in treated and untreated KD patients were
not distinguishable (Additional file 1: Figure S1).
T lymphocyte activation and Type I interferon-induced
genes are upregulated in KD coronary arteries

Pathways associated with activated T lymphocyte function were significantly upregulated in KD coronary arteries (Table 3, Additional file 1: Table S3). Activation
of cytotoxic T lymphocyte genes is consistent with our
prior report demonstrating CD8 protein expression in
KD coronary arteries [13] (Fig. 3a). Although molecular
pathways associated with natural killer cell signaling
were identified as upregulated in KD coronary arteries
(Table 3), there is marked overlap in gene expression by
natural killer cells and activated cytotoxic CD8 T lymphocytes [14], and the lack of an antibody that can reliably
distinguish these two cell types by immunohistochemistry
did not allow us to determine whether natural killer cells
were present in the coronary artery inflammatory infiltrate. In addition, many immunoglobulin genes were upregulated, consistent with our prior immunohistochemical
studies showing immunoglobulin protein expression in
the inflammatory infiltrate [15].
Many type I interferon-stimulated genes [16–18] were
upregulated (Table 4, Fig. 3b). This contrasts with previously reported findings in the peripheral blood of acute

Rowley et al. BMC Genomics (2015) 16:1076

Page 4 of 11

Fig. 1 Workflow to determine differentially expressed molecular pathways in KD coronary arteries

KD patients, in which interferon-stimulated gene expression was reported to be strikingly absent [19]. This result
emphasizes the limitations of peripheral blood studies in
determining gene expression changes in diseased target
tissues.
Antigen presentation and dendritic cell pathways are
activated in KD arteritis

Pathways associated with dendritic cells and antigen presentation were significantly upregulated (Table 3). The activating Fc receptor genes FCGR2A, FCGR2C, FCGR3A,
and FCGR3B, commonly expressed on dendritic cells,
were upregulated, while the inhibitory receptor FCGR2B
and the macrophage marker FCGR1 were not differentially expressed.
Macrophage and neutrophil-specific gene expression are
not prominent

Genes commonly expressed by monocyte/macrophages
[20] were not differentially expressed, such as CD68,
FCGR1A, CSF1R, CD163, and CD14. This contrasts with
a view of KD arteritis as a primarily macrophage-mediated
process [21]. Neutrophil-associated genes were not significantly altered. Eosinophils are a component of the unique
subacute/chronic arteritis infiltrate, and SIGLEC8, which
is selectively expressed by eosinophils and mast cells [22],
was upregulated.

Pattern recognition receptor genes are differentially
expressed in KD arteritis

Pattern recognition receptor genes and Toll-like receptor
signaling pathways were differentially expressed (Table 3).
Many C-type lectin and cytosolic pattern-recognition receptors were differentially expressed (Additional file 1:
Table S2). The most highly upregulated gene in the Tolllike receptor family was TLR7, with TLR1, TLR6, TLR8,
TLR10, TLR5, and TLR2 also upregulated. TLR3, TLR4,
and TLR 9 were not differentially expressed. TLR7 is
thought to be exclusively expressed by plasmacytoid dendritic cells, which secrete type I interferons in response to
viral infection [23].

Genes involved in lipid and lipoprotein metabolism are
differentially expressed in KD arteritis

Many of the differentially expressed genes have functions
in both lipid metabolism and immune response. Genes
commonly associated with promotion of atherogenesis,
such as LDLR and PLA2G2A, were downregulated. A notable feature was the downregulation of surfactant associated genes SFTPA1, SFTPA2, SFTPB, SFTPC, SFTPD,
SFTA2, and SFTA3. It is possible that the marked downregulation in surfactant expression impairs the modulation of inflammatory responses in coronary artery smooth
muscle cells in KD arteritis [24, 25].

Rowley et al. BMC Genomics (2015) 16:1076
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Fig. 2 a Left, coronary artery tissue section from KD patient 6, demonstrating subacute chronic (SA/C) inflammation and luminal myofibroblastic
proliferation (LMP) with resultant narrowing of the arterial lumen that is filled with blood. Right, coronary artery tissue section from control
patient 4, demonstrating normal histology without inflammation. Hematoxylin and eosin stains, M = media, A = adventitia; b Heatmap demonstrating
differential gene expression in KD and control coronary artery tissues, with low expression in blue and high expression in red; c KD coronary artery
gene expression does not cluster by treatment, patient age, or time since onset of KD. The lack of clustering of gene expression by treatment is likely
due to persistent arteritis in the treated patients despite therapy

Rowley et al. BMC Genomics (2015) 16:1076
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Table 3 Top 25 upregulated pathways in kawasaki disease coronary arteries
Upregulated pathways

# of differentially expressed genes

p-value

Primary immunodeficiency signaling

26

5.65E-21

Communication between innate and adaptive immune cells

30

1.08E-17

iCOS-iCOSL signaling in T helper cells

32

3.12E-17

Altered T cell and B cell signaling in rheumatoid arthritis

29

3.84E-17

B cell development

17

3.62E-14

CD28 signaling in T helper cells

28

1.35E-12

Role of NFAT in regulation of the immune response

33

6.43E-12

PKCθ signaling in T lymphocytes

27

8.5E-12

Autoimmune thyroid disease signaling

17

5.1E-11

Hematopoiesis from pluripotent stem cells

17

1.06E-10

T cell receptor signaling

23

1.38E-10

Antigen presentation pathway

14

6.89E-10

Calcium-induced T lymphocyte apoptosis

18

7.03E-10

Crosstalk between dendritic cells and natural killer cells

21

9.61E-10

Systemic lupus erythematosus signaling

34

1.8E-09

Allograft rejection signaling

20

3.16E-09

Graft-versus-host disease signaling

15

3.7E-09

T helper cell differentiation

18

4.41E-09

CTLA4 signaling in cytotoxic T lymphocytes

20

4.84E-09

Nur77 signaling in T lymphocytes

16

6.42E-09

Dendritic cell maturation

29

8.49E-09

Agranulocyte adhesion and diapedesis

29

2.97E-08

OX40 signaling pathway

19

3.48E-08

Natural killer cell signaling

21

5.32E-08

Hepatic fibrosis/Hepatic stellate cell activation

29

7.53E-08

Cytokine and growth factor pathways that were not
differentially expressed

Tumor necrosis factor receptor 1 and 2 signaling pathways
were not differentially expressed (Fig. 3c). Transforming growth factor β signaling was also not differentially
expressed. Interestingly, none of the following genes
were differentially expressed in this dataset: matrix metalloproteinases (with the exception of MMP27, which
just met significance criteria), vascular endothelial growth
factors-A, B, or C, platelet derived growth factors-A,B,C,
or D, vascular cell adhesion molecule 1, or fibroblast
growth factor 2. The interleukin-1 signaling pathway was
not differentially expressed. One IL-1 family member, IL18, was upregulated. However, regulatory IL-1 family
member IL1RN (IL1RA) was also upregulated, and IL1RL1
(IL33R, ST2) was markedly downregulated.
RNA sequencing results are validated by real-time reverse
transcriptase PCR assays

PCR assays confirmed significant upregulation of CD74,
CD69, IL18, HLA-F, NLRC5, and CD226, genes involved

in antigen presentation and dendritic cell function, in
KD CA tissues (Additional file 1: Table S4). Genes that
we previously identified as upregulated by real-time
PCR on KD and control CA, including CD84, PIM2,
POSTN, IL10RA, IL2RA, IQGAP2, and ITGA4 [26–28]
were also identified as significantly upregulated by this
transcriptome analysis, providing additional validation of
our results.

Differentially expressed genes encoding secreted proteins
are candidate biomarkers of KD subacute/chronic arteritis

Extracellular genes encoding secreted proteins accounted
for 155 of the differentially expressed genes (Additional
file 1: Table S5), 93 were upregulated, and 13 were immunoglobulin genes. The other 80 proteins are candidate
diagnostic/prognostic biomarkers of KD arteritis; such
biomarkers are urgently needed for diagnosis and monitoring of KD patients. We have previously reported one of
the upregulated proteins, periostin, as a potential diagnostic biomarker of KD [28].

Rowley et al. BMC Genomics (2015) 16:1076
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Fig. 3 Expression levels of gene families in KD compared with control coronary arteries. a Upregulation of activated cytotoxic CD8 T lymphocyte
genes in KD, b Upregulation of type I interferon-induced genes in KD, c Lack of differential expression of tumor necrosis factor α-induced genes
in KD. Blue indicates low expression and red high expression

No known viral, bacterial, or fungal sequences were
associated with KD

Human and environmental viral sequences were identified in KD and control coronary artery samples, but
none were associated with KD samples (Fig. 4). We
identified the recently described parvovirus-circovirus
hybrid virus as a contaminant in both KD and control
datasets; this virus has previously been shown to contaminate certain nucleic acid isolation kits, and its initial report as a potential cause of human viral hepatitis
highlights the importance of caution in performing
pathogen discovery studies [29]. No specific bacterial
or fungal sequences were associated with KD samples
(data not shown).

Discussion
Identification of upregulated immune pathways in CA
target tissues significantly advances the understanding of
KD pathogenesis, and in particular enhances knowledge
of the molecular immunology of subacute/chronic coronary arteritis. Therapy aimed at reducing CA inflammation in KD patients has been largely empiric, because
of a lack of information regarding the immunopathogenesis of disease in the target CA tissues.

Previous transcriptome studies have been performed
only on peripheral blood of KD patients. Those studies
revealed neutrophil activation prior to treatment with
IGIV, consistent with elevated peripheral blood neutrophil counts during the acute febrile illness [19, 30], and
consistent with the neutrophilic necrotizing arteritis of
medium-sized muscular arteries such as the CA that occurs in the first two weeks after fever onset [4]. Identification of upregulated immune responses in the CA
target tissues of KD provides previously unavailable information with potential therapeutic implications. A recent
rigorous study demonstrated that fold changes in induced
immune response proteins are particularly dominated by
mRNA level changes, whereas expression of cytoskeletal,
metabolic, ribosomal, and mitochondrial proteins are primarily controlled by translation and degradation rates
[31], making it likely that the transcriptional upregulation
identified in this study is accompanied by translational
upregulation.
We found that T lymphocyte activation, antigen presentation and dendritic cell function, immunoglobulin
production, and type I interferon response are the most
significantly upregulated molecular pathways and processes
in KD subacute/chronic arteritis. These are compatible
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Table 4 Type I interferon-stimulated genes differentially expressed
in KD compared with childhood control coronary arteries
Gene
ADAMDEC1
AIM2

Fold change

q-value

Table 4 Type I interferon-stimulated genes differentially expressed
in KD compared with childhood control coronary arteries
(Continued)

20.5

2.6e-18

AGPAT9

−2.4

0.0008

0.023

CES1

−4.1

4.0e-05

3.7

ANKRD22

10.2

1.9e-07

FNDC4

−2.0

0.006

APOBEC3G

3.5

0.023

MT1M

−2.5

0.029

AQP9

4.9

1.7e-06

SAA1

−5.3

6.4e-14

BTN3A3

3.5

0.020

C15orf48

4.0

0.0004

CCL5

6.5

1.1e-05

CD69

10.3

2.6e-09

CD74

7.7

3.5e-05

CLEC2B

3.0

0.006

CLEC4D

3.4

0.029

CLEC4E

3.9

0.011

CXCL9

48.0

1.2e-14

CXCR4

14.7

2.9e-12

EPSTI1

4.9

0.002

FAM46C

5.3

0.001

GBP2

4.3

0.0005

GBP5

14.7

8.8e-14

GK

2.6

0.0008

HLA-F

2.8

0.007

HSH2D

2.9

0.044

IFI30

4.6

0.0002

IFI44

3.3

0.022

IFI44L

4.2

4.6e-06

IFIT2

3.3

0.029

IL1RN

2.8

0.020

MSR1

5.8

0.002

MT1H

1.7

0.0009

MX1

4.2

0.0002

MX2

4.7

0.0005

NCF1

4.1

0.004

OAS1

4.3

0.008

OAS2

5.0

0.0005

OLR1

42.2

7.6e-19

RGS1

17.0

1.3e-10

RSAD2

4.1

0.002

STAP1

7.4

1.3e-07

TAGAP

6.2

0.0001

TFEC

7.4

0.0009

TNFSF13B

4.2

0.010

XAF1

3.3

0.005

ZBP1

5.6

0.002

with the gene polymorphisms resulting in a decrease in
negative regulation of T lymphocyte responses that
have been associated with the development of KD and
CA abnormalities [32, 33]. It is also of interest that several type I interferon-induced proteins such as CXCL9
and CXCL10 are potential biomarkers of KD [34, 35].
Our study did not identify differential expression of the
tumor necrosis factor α pathway, the transforming growth
factor β pathway, matrix metalloproteinases-2,-3, −9 and12, vascular endothelial growth factors, or platelet derived
growth factors, which have been postulated previously
as important players in the pathogenesis of KD arteritis
by us and others [36–39]. These findings do not exclude a role for the previously proposed pathways and
molecules in KD vasculitis pathogenesis, in particular
because gene expression does not always correlate with
protein expression. However, changes in mRNA abundance of immune response genes play the dominant
role in dynamic changes in protein levels, whereas the
proteome of proteins performing basic cellular functions are predominately regulated at the level of protein
translation or degradation [31]. Therefore, the immune
response genes found to be upregulated in our study
may play the most prominent role in KD subacute/
chronic vasculitis.
IGIV non-responders are a high-risk group of patients who are often administered additional immunomodulatory therapies with the goal of improving CA
outcomes. However, identifying optimal therapies for
such patients has been difficult, because the activated
immune pathways in KD CA have been unknown. Because severe CA outcomes can occur even in IGIVtreated patients, particularly young infants, initial studies
of combination primary therapies consisting of IGIV with
a second immunomodulatory agent have been performed.
A single dose of methylprednisolone with IGIV for primary therapy of KD did not improve outcomes [40],
while in the more recent RAISE study, IGIV with a 3–4
week course of prednisolone for primary therapy of
high-risk Japanese children did improve outcomes [41].
It seems plausible that a 2–4 week corticosteroid therapy
course would be more effective in modulating the prominent T lymphocyte responses demonstrated in KD CA tissues in our study than would a single large dose of
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Fig. 4 Heatmap showing viral sequences identified in KD and control coronary artery samples; none were KD-associated by Metastats analyses

methylprednisolone. The use of a tumor necrosis factor-α
inhibitor (infliximab) in combination with IGIV for primary therapy did not result in significantly improved outcomes [39]. The lack of differential expression of the
tumor necrosis α pathway in the present study suggests
that this cytokine may not be an optimal therapeutic target for subacute/chronic arteritis. Chronic type I interferon responses can be involved in the pathogenesis of
persistent viral infections and autoimmune diseases
[42, 43], and therapies to ameliorate this response are
under study [44]. Because 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors appear to have modulatory effects on cytotoxic T lymphocyte responses,
therapeutic trials of these drugs in KD arteritis appear
warranted [45].
Bioinformatics analysis did not reveal any known
viral, bacterial, or fungal sequences associated with KD
coronary artery tissues. There are many potential explanations for the lack of identification of a causative infectious agent in these tissues. The agent could be in a
quantity too low to detect, or could have been eradicated by the immune response earlier in the disease
course, with subacute/chronic arteritis the result of an
inability to resolve the initial inflammatory response.
Another possibility is a “new” agent not present in established reference databases, making it difficult to identify.
Interestingly, our study revealed many upregulated type I
interferon-induced genes in KD CA, which supports our
prior hypothesis of a presently unidentified virus as the
causative agent based on ultrastructural, immunofluorescence, and RNA evidence [2]. We are presently analyzing
KD-associated sequences that remain unassigned in attempts to identify a putative “new” virus, using novel

bioinformatics approaches, such as assembly without a
reference genome [46].
Our study has strengths and limitations. The number
of CA specimens available for study was limited by many
factors. These factors include the fact that CA tissues
are not available for research in the living patient,
reporting of KD deaths is not required, autopsy is sometimes not obtained in fatal cases or is delayed so that
RNA quality is inadequate for molecular studies, and
heart tissues following transplantation are often not optimally preserved for molecular studies. Additional differentially expressed genes might have been identified if
more CA tissues were available for sequencing. Because
necrotizing arteritis is observed in the first 2 weeks after
fever onset, when fatalities or surgical interventions are
rare, our study would not reveal the transcriptome of
necrotizing arteritis [4]. However, subacute/chronic arteritis begins in the first two weeks after fever onset and
can persist for months to years, leading to significant
CA damage [4]. Understanding its pathogenesis is particularly important for IGIV non-responders and for
children with persistent coronary artery abnormalities,
who may have chronic arteritis. KD patients in our study
died or underwent cardiac transplant at various intervals
since KD onset, at various ages, and had received a variety of therapies. However, gene expression did not cluster by these factors (Fig. 2b and c). Tissue samples were
from Caucasian, Hispanic, and Black children but not
Asian children, and from both genders, which could
have affected gene expression results. As sequencing
technology and bioinformatics methods improve, additional studies on larger numbers of KD CA samples, especially from Japan, would be informative to confirm
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and extend the present findings. Over several decades,
we have developed what is likely the largest KD tissue
bank outside of Japan, enabling us to identify the transcriptome of subacute/chronic KD arteritis in this study.
A complete understanding of KD pathogenesis will require integration of genomic, transcriptome, and proteome studies, and identification of the etiologic agent(s).

Conclusions
In summary, the immune transcriptome of KD arteritis in
the patients studied here reveals a marked activation of
cytotoxic and helper T lymphocytes and dendritic cells,
with upregulation of type I interferon responses. These results support a putative viral etiology of KD, and provide
preliminary information on the immunopathogenesis of
KD coronary arteritis that can inform selection of new immunomodulatory therapies for clinical trials in high-risk
patients with this potentially fatal arteritis of childhood.
Supporting data can be accessed at NCBI GEO
GSE64486.
Additional file
Additional file 1: Supplemental Methods. Table S1. RNA sequencing
metrics. Table S2. All differentially expressed genes (8 KD cases vs 7
controls). Table S3. Dysregulated molecular pathways (8 KD cases vs 7
controls). Table S4. Differential expression of genes involved in antigen
presentation and dendritic cell function in KD compared to control
coronary arteries by real-time reverse transcriptase PCR assays. Table S5.
Extracellular genes dysregulated in 8 KD coronary arteries compared with 7
childhood control coronary arteries. Figure S1. Principal components analysis
of all genes in 8 KD (4 treated and 4 untreated) and 7 childhood control
coronary artery tissues demonstrates that gene expression of untreated (red
dots) and treated (black dots) KD patients are not distinguishable. (PDF 382
kb)
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